Immunomodulatory Oligonucleotide IMT504 improves Mesenchymal stem cells proliferation and migration in adult non-obese diabetic mice

GÓMEZ BUSTILLO, SOFÍA; BIANCHI, MARÍA S.; BIANCHI, STEFANIA; BONAVENTURA MARIA; LUX-LANTOS, VICTORIA A.; MONTANER ALEJANDRO

Mar del Plata

Congreso; Reunión anual de Sociedades de Biociencia 2019 (SAIC); 2019

SAIC

Abstract 0394:Type 1 diabetes (T1D) is a multifactorialautoimmune disease in which insulin-producing pancreatic β cellsare destroyed. No effective clinical interventions for T1D arecurrently available, and patients are lifelong treat with insulin.There is a consensus that new innovative approaches are urgently needed to predict, treat, and prevent T1D. Differentstrategies to modulate immunological response and restore β cellmass have been performed, although limited by the availabilityof transplants and the need for chronic immunosuppression.IMT504 is the prototype of the PyNTTTTGT family ofimmunomodulatory oligonucleotides (ODNs) known for theirregenerative properties and proven to be effective in loweringglycemia in non-obese diabetic (NOD) mice. Here, we investigateits action in bone marrow mesenchymal stem cells (BM-MSCs)and splenocytes in NOD/LtJ. BM-MSCs and splenocytes from prediabetic and diabetic NOD mice were treated, in vitro, withdifferent doses of IMT504 (0.5, 1.5, 4, 6.5, 10.5 and 20 µg/ml).No differences were observed in splenocytesactivation/proliferation at higher doses. Fibroblasts colonyforming units (CFU-F) that originate MSCs, viability, andmigration assays were assessed. It was determined that 0.5µg/ml of IMT504 stimulated MSCs (CFU-F (106 seed cells/cm2):IMT504: 85 vs. Control: 65 p